Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers

E. Conde, B. Angulo, E. Izquierdo, L. Paz-Ares, C. Belda-Iniesta, M. Hidalgo, F. López-Ríos

Research output: Contribution to journalArticle

Abstract

The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.

Original languageEnglish (US)
Pages (from-to)503-508
Number of pages6
JournalClinical and Translational Oncology
Volume15
Issue number7
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Biomarkers
Non-Small Cell Lung Carcinoma
Histology
Therapeutics
Biopsy
Adenocarcinoma of lung
Neoplasms

Keywords

  • ALK
  • Biomarkers
  • EGFR
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lung adenocarcinoma in the era of targeted therapies : Histological classification, sample prioritization, and predictive biomarkers. / Conde, E.; Angulo, B.; Izquierdo, E.; Paz-Ares, L.; Belda-Iniesta, C.; Hidalgo, M.; López-Ríos, F.

In: Clinical and Translational Oncology, Vol. 15, No. 7, 07.2013, p. 503-508.

Research output: Contribution to journalArticle

Conde, E. ; Angulo, B. ; Izquierdo, E. ; Paz-Ares, L. ; Belda-Iniesta, C. ; Hidalgo, M. ; López-Ríos, F. / Lung adenocarcinoma in the era of targeted therapies : Histological classification, sample prioritization, and predictive biomarkers. In: Clinical and Translational Oncology. 2013 ; Vol. 15, No. 7. pp. 503-508.
@article{666e727b2c614a159097e5e1c11cc51c,
title = "Lung adenocarcinoma in the era of targeted therapies: Histological classification, sample prioritization, and predictive biomarkers",
abstract = "The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.",
keywords = "ALK, Biomarkers, EGFR, Lung cancer",
author = "E. Conde and B. Angulo and E. Izquierdo and L. Paz-Ares and C. Belda-Iniesta and M. Hidalgo and F. L{\'o}pez-R{\'i}os",
year = "2013",
month = "7",
doi = "10.1007/s12094-012-0983-z",
language = "English (US)",
volume = "15",
pages = "503--508",
journal = "Clinical and Translational Oncology",
issn = "1699-048X",
publisher = "Springer-Verlag Italia",
number = "7",

}

TY - JOUR

T1 - Lung adenocarcinoma in the era of targeted therapies

T2 - Histological classification, sample prioritization, and predictive biomarkers

AU - Conde, E.

AU - Angulo, B.

AU - Izquierdo, E.

AU - Paz-Ares, L.

AU - Belda-Iniesta, C.

AU - Hidalgo, M.

AU - López-Ríos, F.

PY - 2013/7

Y1 - 2013/7

N2 - The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.

AB - The arrival of targeted therapies has presented both a conceptual and a practical challenge in the treatment of patients with advanced non-small cell lung carcinomas (NSCLCs). The relationship of these treatments with specific histologies and predictive biomarkers has made the handling of biopsies the key factor for success. In this study, we highlight the balance between precise histological diagnosis and the practice of conducting multiple predictive assays simultaneously. This can only be achieved where there is a commitment to multidisciplinary working by the tumor board to ensure that a sensible protocol is applied. This proposal for prioritizing samples includes both recent technological advances and the some of the latest discoveries in the molecular classification of NSCLCs.

KW - ALK

KW - Biomarkers

KW - EGFR

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84879799050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879799050&partnerID=8YFLogxK

U2 - 10.1007/s12094-012-0983-z

DO - 10.1007/s12094-012-0983-z

M3 - Article

C2 - 23359174

AN - SCOPUS:84879799050

VL - 15

SP - 503

EP - 508

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

SN - 1699-048X

IS - 7

ER -